GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Wuxi AppTec Co Ltd (SHSE:603259) » Definitions » COGS-to-Revenue

Wuxi AppTec Co (SHSE:603259) COGS-to-Revenue : 0.59 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Wuxi AppTec Co COGS-to-Revenue?

Wuxi AppTec Co's Cost of Goods Sold for the three months ended in Dec. 2023 was ¥6,387 Mil. Its Revenue for the three months ended in Dec. 2023 was ¥10,799 Mil.

Wuxi AppTec Co's COGS to Revenue for the three months ended in Dec. 2023 was 0.59.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Wuxi AppTec Co's Gross Margin % for the three months ended in Dec. 2023 was 40.85%.


Wuxi AppTec Co COGS-to-Revenue Historical Data

The historical data trend for Wuxi AppTec Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuxi AppTec Co COGS-to-Revenue Chart

Wuxi AppTec Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.61 0.62 0.64 0.63 0.59

Wuxi AppTec Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 0.60 0.59 0.57 0.59

Wuxi AppTec Co COGS-to-Revenue Calculation

Wuxi AppTec Co's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=23728.8 / 40340.807
=0.59

Wuxi AppTec Co's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=6387.493 / 10799.481
=0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Wuxi AppTec Co  (SHSE:603259) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Wuxi AppTec Co's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 6387.493 / 10799.481
=40.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Wuxi AppTec Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Wuxi AppTec Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Wuxi AppTec Co (SHSE:603259) Business Description

Traded in Other Exchanges
Address
288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, CHN, 200131
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services through the discovery, development, and manufacturing spectrum for small-molecule drugs, cell therapies, and gene therapies as well as providing testing services for medical devices. Its segments comprise China-based laboratory services; U.S.-based laboratory services; Clinical research and other CRO services; CDMO services; and Others. The majority of revenue gets derived from China-based laboratory services that include small molecules discovery, such as synthetic chemistry, medicinal chemistry, analytical chemistry, biology, drug metabolism and pharmacokinetics (DMPK)/absorption, distribution, metabolism, and excretion (ADME), toxicology and bioanalytical services.

Wuxi AppTec Co (SHSE:603259) Headlines

No Headlines